Drug profile · INN
tripelennamine citrate
PBZ
tripelennamine citrate (PBZ) is a histamine h1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — tripelennamine citrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
tripelennamine citrate (PBZ) is a histamine h1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Histamine H1 receptor antagonist
Primary target: Histamine H1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is tripelennamine citrate?
tripelennamine citrate (PBZ) is a histamine h1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tripelennamine citrate?
PBZ is a marketed brand name for tripelennamine citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tripelennamine citrate?
tripelennamine citrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.